ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Datopotamab deruxtecan for endocrine-resistant HR-positive/HER2-negative breast cancer: biological rationale and clinical evidence.
Bhargavi Gumma et al.PubMed ↗Publisher ↗
No numbers read from the abstract.